Attributable Mortality of Candida Bloodstream Infections in the Modern Era: A Propensity Score Analysis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background: This study quantifies the mortality attributable to Candida bloodstream infections (BSI) in the modern era of echinocandins. Methods: We conducted a retrospective cohort study of adult patients admitted to Barnes Jewish Hospital, a 1368-bed tertiary care academic hospital, in Saint Louis, Missouri, from 1 February 2012 to 30 April 2019. We identified 626 adult patients with Candida BSI that were frequency-matched with 6269 control patients that had similar Candida BSI risk-factors. The 90-day all-cause mortality attributable to Candida BSI was calculated using three methods—propensity score matching, matching by inverse weighting of propensity score, and stratified analysis by quintile. Results: The 90-day crude mortality was 42.4% (269 patients) for Candida BSI cases and 17.1% (1083 patients) for frequency-matched controls. Following propensity score-matching, the attributable risk difference for 90-day mortality was 28.4% with hazard ratio (HR) of 2.12 (95% confidence interval [CI], 1.98–2.25, P < .001). In the stratified analysis, the risk for mortality at 90 days was highest in patients in the lowest risk quintile to develop Candida BSI (hazard ratio [HR] 3.13 (95% CI, 2.33–4.19). Patients in this lowest risk quintile accounted for 81(61%) of the 130 untreated patients with Candida BSI. Sixty-nine percent of untreated patients (57/83) died versus 35% of (49/127) of treated patients (P < .001). Conclusions: Patients with Candida BSI continue to experience high mortality. Mortality attributable to Candida BSI was more pronounced in patients at lowest risk to develop Candida BSI. A higher proportion of these low-risk patients went untreated, experienced higher mortality, and should be the target of aggressive interventions to ensure timely, effective treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Candidemia has been found to increase 90-day mortality rates by >28%.1”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [1]
Citations
Cites
Comorbidity measures for use with administrative data.
Elixhauser, A., Steiner, C., Harris, D. R., & Coffey, R. M. (1998) · Medical Care · doi:10.1097/00005650-199801000-00004 · Cited by 9,921
Austin, P. C. (2009) · Statistics in Medicine · doi:10.1002/sim.3697 · Cited by 6,758
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Austin, P. C. (2011) · Pharmaceutical Statistics · doi:10.1002/pst.433 · Cited by 3,949
Variable Selection for Propensity Score Models
Brookhart, M. A., Schneeweiss, S., Rothman, K. J., Glynn, R. J., Avorn, J., & Stürmer, T. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj149 · Cited by 2,336
Pappas, P. G., Lionakis, M. S., Arendrup, M. C., Ostrosky-Zeichner, L., & Kullberg, B. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.26 · Cited by 1,636
Austin, P. C. (2014) · Statistics in Medicine · doi:10.1002/sim.5984 · Cited by 1,422
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Kullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Changes in prevalence of health care-associated infections in U.S. hospitals
Magill, S. S., O’Leary, E., Janelle, S. J., Thompson, D. L., Dumyati, G., Nadle, J., Wilson, L. E., Kainer, M. A., Lynfield, R., Greissman, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801550 · Cited by 1,249
Research works printed but not linked: 1
- Rentz, 1998, The impact of candidemia on length of hospital stay, outcome, and overall cost of illness., Clin Infect Dis, 27, 781, 10.1086/514955 · DOI · Paper page
Cited by
Lass-Flörl, C., Kanj, S. S., Govender, N. P., Thompson, G. R., Ostrosky- Zeichner, L., & Govrins, M. A. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00503-3 · Cited by 298
“Invasive candidiasis in health-care settings is an infection with high consequences with overall and attributable mortality of ~30–40% 146 .”
Hoenigl, M., Salmanton-García, J., Egger, M., Gangneux, J.-P., Bicanic, T., Arikan-Akdagli, S., Alastruey-Izquierdo, A., Klimko, N., Barac, A., Özenci, V., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00872-6 · Cited by 152
Salmanton-García, J., Cornely, O. A., Stemler, J., Barać, A., Steinmann, J., Siváková, A., Akalin, E. H., Arikan-Akdagli, S., Loughlin, L., Toscano, C., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106229 · Cited by 127
Epidemiology of Invasive Candidiasis
Bays, D., Jenkins, E., Lyman, M., Chiller, T., Strong, N., Ostrosky-Zeichner, L., Hoenigl, M., Pappas, P., & Thompson, G. (2024) · Clinical Epidemiology · doi:10.2147/clep.s459600 · Cited by 109
Thompson, G. R., Soriano, À., Honoré, P. M., Bassetti, M., Cornely, O. A., Kollef, M. H., Kullberg, B. J., Pullman, J. R., Hites, M., Fortün, J., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00551-0 · Cited by 94
“A small proportion of patients (five [4”
Simon, S. P., Li, R., Silver, M., Andrade, J., Tharian, B., Fu, L., Villanueva, D., Abascal, D. G., Mayer, A., Truong, J., et al. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac735 · Cited by 56
Wolfgruber, S., Sedik, S., Klingspor, L., Tortorano, A. M., Gow, N. A. R., Lagrou, K., Gangneux, J., Maertens, J. A., Meis, J. F. G. M., Lass‐Flörl, C., et al. (2024) · Mycopathologia · doi:10.1007/s11046-024-00871-0 · Cited by 44
A synthetic peptide mimic kills Candida albicans and synergistically prevents infection
Schaefer, S., Vij, R., Sprague, J. L., Austermeier, S., Dinh, H., Judzewitsch, P. R., Müller‐Loennies, S., Silva, T. L., Seemann, E. A., Qualmann, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50491-x · Cited by 45
“Candida spp. is the fourth most common cause of hospital-acquired infections, and mortality rates from systemic Candida infections exceed 40%, even with antifungal intervention 3,5 .”
Agnelli, C., Guimarães, T., Sukiennik, T., Lima, P. R. P., Salles, M. J. C., Breda, G. L., Queiroz‐Telles, F., Magri, M. M. C., Mendes, A. V. A., Camargo, L. F. A., et al. (2023) · Journal of Fungi · doi:10.3390/jof9040468 · Cited by 30
“Likewise, in a recent study investigating the attributed mortality of candidemia in the modern era, there was still around 20% of untreated patients who not only experienced even higher mortality rates, but curiously, most of them were classified as unsuspected cases, in patients presenting the lowest risk of developi…”
BackgroundSchaefer, S., Melodia, D., Pracey, C. P., Corrigan, N. A., Lenardon, M. D., & Boyer, C. A. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.3c01038 · Cited by 21
Derkacz, D., & Krasowska, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043966 · Cited by 18
“Candida-related infections are responsible for the high mortality rate of hospitalized patients ranging from 30 to 80% [29,30].”
BackgroundZhang, D., Lan, X., Cai, M., Liao, Y., Zhang, J., Ye, N., Lu, X., Wang, J., Xiao, Y., Zhang, Y., et al. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1504866 · Cited by 20
Effect of Star Topology Versus Linear Polymers on Antifungal Activity and Mammalian Cell Toxicity
Schaefer, S., Melodia, D., Corrigan, N. A., Lenardon, M. D., & Boyer, C. A. (2023) · Macromolecular Bioscience · doi:10.1002/mabi.202300452 · Cited by 17
Combatting Fungal Infections: Advances in Antifungal Polymeric Nanomaterials
Schaefer, S., Corrigan, N. A., Brunke, S., Lenardon, M. D., & Boyer, C. A. (2024) · Biomacromolecules · doi:10.1021/acs.biomac.4c00866 · Cited by 19
Stewart, A. G., Laupland, K. B., Edwards, F., Koo, S., Hammond, S. P., Harris, P. N. A., Paterson, D. L., Slavin, M. A., & Chen, S. C.-A. (2025) · Journal of Infection · doi:10.1016/j.jinf.2025.106513 · Cited by 21
Zuniga-Moya, J. C., Papadopoulos, B., Mansoor, A., Mazi, P. B., Rauseo, A. M., & Spec, A. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae108 · Cited by 17
Self-citationThompson, G. R., Chastain, D. B., Ferraz, C., Alhayek, S., Salinas, J. L., Sillau, S., Stenehjem, E. A., & Henao‐Martínez, A. F. (2024) · Medical Mycology · doi:10.1093/mmy/myae122 · Cited by 19
Outcomes of Fungemia in Patients Receiving Extracorporeal Membrane Oxygenation
Rosas, M. M., Sobieszczyk, M. J., Warren, W. A., Mason, P. E., Walter, R. J., & Marcus, J. E. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac374 · Cited by 15
“Fungemia is associated with a high attributable mortality [5].”
BackgroundHirai, T., & Nashi, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217537 · Cited by 14
“Although the prognosis of oral and esophageal candidiasis is generally favorable, severe cases may result in systemic dissemination, especially in immunocompromised hosts [20,21].”
Soriano, À., Honoré, P. M., Cornely, O. A., Chayakulkeeree, M., Bassetti, M., Haihui, H., Dupont, H., Kim, Y. K., Kollef, M. H., Kullberg, B. J., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae363 · Cited by 10
Singh, R., Ali, M. S., & Dubey, A. K. (2024) · Archives of Microbiology · doi:10.1007/s00203-023-03788-2 · Cited by 7
“Despite improvements in healthcare facilities for the treatment, invasive candidiasis continues to be associated with a high rate of mortality and morbidity (Bassetti et al. 2006; Belghit et al. 2016; Mazi et al. 2022).”
Ryder, J. H., Schooneveld, T. C. V., Lyden, E. R., Ramahi, R. E., & Stohs, E. J. (2022) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2022.209 · Cited by 7
Shared metabolism between a bacterial and fungal species that reside in the human gut
Gause, H., & Johnson, A. D. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2504785122 · Cited by 5
“These fungal blooms have been observed to precede the onset of intestinal inflammation, epithelial barrier dysfunction, and translocation of C. albicans from the gut to bloodstream where it can cause systemic infection with mortality rates as high as 40% ( 16 – 18 ).”
Gmedhin, H., Wu, P., Gu, Z., Lenardon, M. D., & Boyer, C. A. (2025) · European Polymer Journal · doi:10.1016/j.eurpolymj.2025.114384 · Cited by 5
Kumar, A., Kumar, A., Tyagi, A., Singh, R., & Charaya, M. U. (2026) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-026-05577-3 · Cited by 7
Vergidis, P. I., Ordaya, E. E., Porter, E., Sweet, H., Wang, W. J., Evans, A. F., Zhang, C., Young, J. H., & Liu, X. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf068 · Cited by 5
Challenges posed by fungi to host immunity: Mechanisms of immune evasion
Gu, Y., Wang, H., Wang, Y.-S., Wang, L., & Jia, X.-M. (2026) · hLife · doi:10.1016/j.hlife.2025.12.008 · Cited by 5
“Invasive candidiasis, primarily driven by species such as Candida albicans , Candida auris, and Candida parapsilosis , exhibits mortality rates as high as 30%–40% and often leads to severe complications, including end-organ damage, osteomyelitis, and blindness from Candida endophthalmitis [6,7].”
Experimental study of specific and nonspecific blood culture bottles for the diagnosis of candidemia
Wilot, L. C., Poester, V. R., Severo, C. B., Sanchotene, K. O., Esperon, B. M., Trápaga, M. R., Stevens, D. A., & Xavier, M. O. (2024) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2024.06.001 · Cited by 4
Logan, C., Allebone-Salt, P. E., Mazzella, A., Hemsley, C. J., Goodman, A. L., Ward, C., Fife, A., Schelenz, S., Abdolrasouli, A., & Bicanic, T. A. (2026) · Journal of Infection · doi:10.1016/j.jinf.2026.106692 · Cited by 7
Cai, G., & Zhang, Z. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01617-25 · Cited by 5
Dellai, F., Pagotto, A., Sbrana, F., Ripoli, A., Danieli, G., Colombo, A. E., D’Elia, D., Geminiani, M., Giuliano, S., Sartor, A., et al. (2025) · Journal of Fungi · doi:10.3390/jof11050400 · Cited by 3
“In comparison to other European cohorts, our study reported higher mortality, particularly at 30 days (50% vs. 43%), likely reflecting the older median age of our population (73 vs. 65–68 years) [2,5,7,22,34,35,42].”
InfluentialMundhe, A. K., & Rajkumari, R. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1687392 · Cited by 4
“Drug-resistant C. albicans strains now account for a substantial proportion of treatment failures in hospital-acquired infections (Brown et al., 2012; Mazi et al., 2022; Aldardeer et al., 2020; Arendrup and Patterson, 2017).”
Editing Candida: Origins and Advances of CRISPR Tools
Schulze, A., Kainz, K., Bauer, M. A., & Carmona‐Gutiérrez, D. (2026) · Biomolecules · doi:10.3390/biom16020245 · Cited by 4
Synergistic anti-Candida effects of essential oil blends on biofilms at various maturation stages
Balázs, V. L., Puskár, L., Ormai, E., Farkas, Á., Utczás, M., Kocsis, B., Papp, N., Kerekes, E. B., Biró, V., & Kocsis, M. (2026) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2026.107515 · Cited by 3
Functional analysis of Candida albicans Cdr1 through homologous and heterologous expression studies
Zhao, M., Lamping, E., Niimi, K., Niimi, M., & Cannon, R. D. (2025) · FEMS Yeast Research · doi:10.1093/femsyr/foaf012 · Cited by 3
“The majority of IFIs are caused by Candida species and Candida blood stream infections have a high attributable mortality of ∼ 28% (Mazi et al. 2022 , Lass-Florl et al. 2024 ).”
Cohen, N., Orenbuch‐Harroch, E., Olshtain‐Pops, K., Lachish, T., & Korem, M. (2023) · Mycopathologia · doi:10.1007/s11046-023-00755-9 · Cited by 3
“The one-year mortality rate was similar to mortality rates described formerly [2].”
ResultShimosato, M., Kada, S., Yase, E., & Sakane, N. (2024) · Special Care in Dentistry · doi:10.1111/scd.12955 · Cited by 3
Madduri, M., Rudramurthy, S. M., & Roy, U. (2025) · ACS Omega · doi:10.1021/acsomega.5c06938 · Cited by 4
Rezai, M. S., & Ahangarkani, F. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00046-4 · Cited by 3
Matzko, M. E., Sephton-Clark, P., Young, E. L., Jhaveri, T. A., Martinsen, M. A., Mojica, E., Boykin, R., Pierce, V., Cuomo, C. A., & Bhattacharyya, R. P. (2022) · Medical Mycology · doi:10.1093/mmy/myac065 · Cited by 3
Ford, D., Reveles, K. R., Hoban, C., Koutoubi, S., & Cadena, J. (2023) · American Journal of Infection Control · doi:10.1016/j.ajic.2023.10.002 · Cited by 2
Mundhe, A. K., Premanand, A., & Baskaran, R. R. (2026) · In Silico Pharmacology · doi:10.1007/s40203-025-00480-9 · Cited by 3
“As per literature survey during 2015 to 2022 the candidemia alone is responsible for over 70% of these deaths, resulting in over 1.5 million fatalities worldwide annually (Mazi et al. 2022 ; Kullberg and Arendrup 2015 ; Pappas et al. 2016; Pappas et al. 2018).”
InfluentialAntibiotic Considerations in the Critically Ill
Gillett, E. M., Dube, K. M., & Rhee, C. (2026) · Critical Care Clinics · doi:10.1016/j.ccc.2026.01.003 · Cited by 1
Scaglione, G., Colaneri, M., Offer, M., Montrucchio, G. G., Genovese, C., Viaggi, B., Dore, F., Tricella, G., Dalfino, L., Monti, G., et al. (2026) · Critical Care · doi:10.1186/s13054-026-05886-1 · Cited by 1
Candida in the ICU, Risk Management and Patient Safety
Nolla-Salas, M., & Ibáñez, J. (2026) · Microorganisms · doi:10.3390/microorganisms14061200 · Cited by 1
“Crude ICU mortality ranges from 28% to 50% [53–57], while attributable mortality has been estimated between 15% and 50% [18,58–60].”
Yasuma-Mitobe, K., Liao, C., Németh, T., Byrne, K. P., Billips, A., Ramos, R. J. J. F., Salinas, C. N., Chan, E., Perissinoto, M., Adami-Sampson, S., et al. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.05.008 · Cited by 4
Colombo, A. L., Magri, M. M. C., Carlesse, F. A. D. M. C., Falci, D. R., Garnica, M., Santos, D. W. D. C. L., Queiroz‐Telles, F., & Pasqualotto, A. C. (2026) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2026.105946 · Cited by 2
Kim, K. J., Yoon, Y. K., Kim, J. Y., Kim, M. J., Sohn, J. W., & Nam, M. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag511 · Cited by 3
Genomic Innovation and Virulence Evolution in the Emerging Human Fungal Pathogen Candida auris
Gifford, H., Rhodes, J. L., Wilson, D., & Farrer, R. A. (2024) · The mycota · doi:10.1007/978-3-031-75666-5_10 · Cited by 2
Hirnle, G., Kapałka, M., Krawiec, M., & Hrapkowicz, T. (2024) · IDCases · doi:10.1016/j.idcr.2024.e01949
“Candidemia itself presents a substantial mortality rate, as Mazi reported, reaching 42.2 % [6].”
BackgroundInfluentialWeng, K.-Z., Wu, C., Zhuang, S., Huang, S., Wang, X., & Zheng, Y. (2024) · PubMed Central · doi:10.7499/j.issn.1008-8830.2406021
Candidemie e candidosi invasive
Benitha, Y., & Bleibtreu, A. (2025) · EMC - Anestesia-Rianimazione · doi:10.1016/s1283-0771(24)49999-4
Candidemia y candidiasis invasiva
Benitha, Y., & Bleibtreu, A. (2025) · EMC - Anestesia-Reanimación · doi:10.1016/s1280-4703(25)50394-8
Mathur, V., & Amar, P. K. (2025) · Indian Journal of ECMO · doi:10.5005/jaypee-journals-11011-0035
Mansoor, A., Krishnan, G., Zuniga-Moya, J. C., Papadopoulus, B., Spec, A., & George, I. A. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf504
“Candida BSI are an important cause of healthcare-associated BSI and associated with a high risk of mortality and morbidity [10].”
InfluentialSelf-citationYasuma-Mitobe, K., Liao, C., Németh, T., Byrne, K. P., Billips, A., Ramos, R. J. J. F., Salinas, C. N., Chan, E., Perissinoto, M., Sidebottom, A. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.12.675697
Liu, M., Liu, R., Liu, Z., He, K., & Chen, L. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-12557-7
“Studies indicate a mortality rate of up to 40% for candidemia, emphasizing the urgency of antimicrobial stewardship and vigilance against deep-seated fungal infections [30].”
Treviño‐Rangel, R. D. J., Villanueva‐Lozano, H., González-Lara, M. F., Castaño-Jiménez, P. A., Corte-Rojas, R. E., Quevedo-Ramos, M. A., Avilés-Benítez, L. K., López-Gutiérrez, E., Feliciano-Guzmán, J. M., Río, M. D.-D., et al. (2026) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-026-05452-1 · Cited by 1
Yoshida, H., Adelman, M. W., Rasmy, L., Ifiora, F., Xie, Z., Pérez, M. A., Guerra, F. M., Yoshimura, H., Jones, S. L., Arias, C. A., et al. (2026) · EClinicalMedicine · doi:10.64898/2026.03.03.26347531
Ostrosky-Zeichner, L. L., Aram, J. A., Redell, M. A., Thompson, G. R., Cornely, O. A., McKinnell, J. A., Spec, A., & Pappas, P. G. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag143
Self-citationSergounioti, A., Rigas, D., & Kalles, D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.12.724346
“…species are a leading cause of invasive fungal infections in hospitalised patients, with invasive candidiasis and candidemia associated with substantial crude mortality, commonly reported in the range of 30–60% depending on patient population, species distribution, and clinical context (1–3).”
Liu, Z., Li, M., Wang, J. X., & Chen, B. (2026) · Medical Mycology · doi:10.1093/mmy/myag063 · Cited by 1
Endo, A., Hanai, Y., Mikawa, T., Asakawa, D., Ishibe, T., Nakane, Y., Tanaka, M., Mitsui, D., Kido, S., Nonaka, T., et al. (2026) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-026-05601-6
Miyagawa, A., Nakagawa, S., Hagiwara, T., Yamamoto, Y., Imada, T., Inaba, N., Kato, H., Masuda, K., Osawa, K., & Yamamura, H. (2026) · RSC Advances · doi:10.1039/d6ra02945k
Alduwayrij, A., Alarfaj, A., Alarbash, M., Parvez, M., Albanyan, O. A., Alquhays, I. A., Alshanqiti, A. A. M., Albaarrak, Y. A., Eldirdiri, S., & Absar, M. M. (2026) · International Journal of Microbiology · doi:10.1155/ijm/6422952
Sprute, R., Singh, S., Conti, H. R., Cornely, O. A., van de Veerdonk, F. L., Carvalho, A., & Ibrahim, A. S. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.08.043
Pan, S.-C., Chang, P.-H., Lin, G.-L., Lin, Y., Lee, I., Chen, Y., & Lee, C. (2026) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2026.09.003
Shahzad, M., Amin, M. K., Munir, A. B. I., Patan, S., Rukh, S., Akbari, A. R., Khaliq, A., Yaseen, L., Humayun, M. A., Zaheer, A., et al. (2026) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2026.07.004
Metadata
- Authors
- Mazi, P. B., Olsen, M. A., Stwalley, D., Rauseo, A. M., Ayres, C., Powderly, W. G., & Spec, A.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Spec, Andrej
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-01-05
- Volume
- 75
- Issue
- 6
- Pages
- 1031-1036
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC10233239
- OpenAlex
- W4206789835
- Cited by
- 68
- References
- 31
- Citations by year
- 2026: 26 · 2025: 14 · 2024: 16 · 2023: 8 · 2022: 4
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Astellas Global Development Pharma (MYCA-15L03)
- Washington University Institute of Clinical and Translational Sciences
- National Center for Advancing Translational Sciences
- National Institutes of Health (TR002345)
- Agency for Healthcare Research and Quality (R24 HS19455)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, echinocandins, antifungal therapy, low-risk patients, 90-day mortality, propensity score matching, risk stratification
- MeSH terms
- Adult, Candida, Candidiasis, Humans, Retrospective Studies, Sepsis, Echinocandins, Propensity Score
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.